{"id":"W2954887335","doi":"10.1212/nxi.0000000000000590","title":"Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP","year":2019,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Japan Society for the Promotion of Science; Sanofi Genzyme; Novartis Pharma; Grifols; Ono Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Teijin Pharma; Bayer Yakuhin; Celgene; Ministry of Education, Culture, Sports, Science and Technology; Pfizer Japan; Shionogi; Argenx; Ministry of Health, Labour and Welfare; Eisai; Japan Blood Products Organization; Boehringer Ingelheim Japan; Kissei; Neurocrine Biosciences; Pfizer; Biogen; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Heinrich-Heine-Universität Düsseldorf; Bristol-Myers Squibb; GBS/CIDP Foundation International; Teva Pharmaceutical Industries; Myasthenia Gravis Foundation of America; Bayer HealthCare; Kowa Company; Sanofi; CSL Behring","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Adverse effect; Internal medicine; Polyradiculoneuropathy; Gastroenterology; Surgery; Antibody; Pediatrics; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001760739,0.0003619745,0.0007970907,0.0004016156,0.00006839511,0.00001358168,0.0002217696,0.0003214311,0.0001564085],"category_scores_gemma":[0.0002840267,0.0003687784,0.000136614,0.0003863114,0.0003789222,0.0001621009,0.000194295,0.0008898593,0.00007256527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001933908,"about_ca_system_score_gemma":0.00007962333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003718494,"about_ca_topic_score_gemma":0.00005183836,"domain_scores_codex":[0.997179,0.0003996587,0.000921617,0.0007620053,0.0002127968,0.0005249273],"domain_scores_gemma":[0.998341,0.0003997786,0.0003461457,0.000748358,0.00008567863,0.00007902735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01446974,0.0003417369,0.4711777,0.000185502,0.00003966199,0.001709942,0.0001821859,0.0002449294,0.4975643,0.0003534917,0.00001850253,0.01371223],"study_design_scores_gemma":[0.006331578,0.004141252,0.9833794,0.00003773512,0.00005146522,0.00322775,0.000009407061,0.0005141117,0.001526935,0.00004730572,0.0005260398,0.0002070454],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938254,0.0005584218,0.00001001636,0.00256151,0.0007157595,0.001114104,0.000004892162,0.0001216041,0.001088321],"genre_scores_gemma":[0.9971622,0.001277848,0.00002344307,0.001191596,0.00003303967,0.000009966067,0.00003417232,0.0000610077,0.0002067082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5122016,"threshold_uncertainty_score":0.9998764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00639744829432481,"score_gpt":0.2298394140922261,"score_spread":0.2234419657979012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}